01
Company
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Supply Chain Management
02
Products & Services
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
03
Investors
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
04
Newsroom
Contact Us
Language
Languages
English
Chinese
Alvogen Korea
Company
Products & Services
Investors
Newsroom
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Supply Chain Management
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
Skip Navigation
Investors
A Fast Growing Contender in Global Generics
Meet Management
Newsroom
In Focus
All articles
Investors
10 February 2026
Lotus Reports January 2026 Revenue of NT$2,052 Million
Investors
12 January 2026
Lotus Reports December 2025 Revenue of NT$2,442 Million, Driven by Consolidation of Strategic Alvogen US Acquisition
Investors
10 December 2025
Lotus Reports November 2025 Revenue of NT$1,059 Million
Stock Information
Lotus is listed on Taiwan Stock Exchange
Code: 1795
Stock Quote
Market Observation Post System
TWSE, Taipei 101
Links
Document Center
Financial Information
Monthly sales
Quarterly Reports and Presentations
Shareholders Services
Shareholders meetings
Contacts
